미분류

Celltrion’s biosimilar prescribed over 100,000 times in Europe

By 황유미
  • Published : Aug 30, 2016 - 17:31
  • Updated : Aug 30, 2016 - 17:31
[THE INVESTOR] Biopharmaceutical company Celltrion announced on Aug. 30 that its biosimilar Remsima has been prescribed for more than 105,000 patients in Europe by end-June since its launch in August 2013.

As the number of European patients who were prescribed Janssen’s Remicade (infliximab), the original drug to treat rheumatoid arthritis and autoimmune diseases, is estimated to be about 260,000, the biosimilar version is taking up about 40 percent of its market share, according to the company.

By Hwang You-mee (glamazon@heraldcorp.com)